Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 5/20 | 0.58 |
| ▸ | CA2 | P00918 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 4/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.41 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.39 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19627155 | 0.86 | CA2 (0.52) | CYP2A6CA2LMNATP53KEAP1 | |
| SCHEMBL5178978 | 0.85 | LMNA (0.58) | CYP2A6CA2LMNATP53SMN1; SMN2 | |
| SCHEMBL10266973 | 0.83 | CA2 (0.60) | CYP2A6CA2LMNATP53KEAP1 | |
| SCHEMBL14155053 | 0.82 | CA2 (0.49) | CYP2A6CA2LMNAKEAP1NFE2L2 | |
| SCHEMBL14395870 | 0.81 | CA2 (0.55) | CYP2A6CA2LMNATP53KEAP1 | |
| SCHEMBL5179133 | 0.81 | CA2 (0.55) | CYP2A6CA2LMNATP53SMN1; SMN2 | |
| SCHEMBL3276210 | 0.81 | CA2 (0.55) | CYP2A6CA2LMNATP53KEAP1 | |
| SCHEMBL1520186 | 0.80 | KEAP1 (0.68) | CA2TP53SMN1; SMN2RXFP1KEAP1 | |
| SCHEMBL19627157 | 0.79 | CA2 (0.52) | CYP2A6CA2LMNATP53KEAP1 | |
| SCHEMBL9751556 | 0.79 | CA2 (0.56) | CYP2A6CA2TP53MAPTUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1249450-B1 | BENZIMIDAZOLE DERIVATIVES AS HUMAN CHYMASE INHIBITORS | TEIJIN PHARMA LTD (JP) | 2007-10-10 | — | — | EP | disclosed |
| EP-1249450-B1 | BENZIMIDAZOLE DERIVATIVES AS HUMAN CHYMASE INHIBITORS | TEIJIN PHARMA LTD (JP) | 2007-10-10 | — | — | EP | disclosed |
| US-7176320-B2 | Benzimidazole derivative | TEIJIN LIMITED (JP) | 2007-02-13 | — | — | US | disclosed |
| US-7176320-B2 | Benzimidazole derivative | TEIJIN LIMITED (JP) | 2007-02-13 | — | — | US | disclosed |
| US-7176320-B2 | Benzimidazole derivative | TEIJIN LIMITED (JP) | 2007-02-13 | — | — | US | disclosed |
| US-20050267148-A1 | Benzimidazole derivative | TEIJIN LIMITED | 2005-12-01 | — | — | US | disclosed |
| US-20040162311-A1 | Benzimidazole derivative | TEIJIN LIMITED | 2004-08-19 | — | — | US | disclosed |
| US-20040010004-A1 | Benzimidazole derivatives | TEIJIN LIMITED (JP) | 2004-01-15 | — | — | US | disclosed |
| EP-1249450-A1 | BENZIMIDAZOLE DERIVATIVES | TEIJIN LIMITED (JP) | 2002-10-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040162311-A1 | Benzimidazole derivative | CMA1, CBR3, CBR1 | CYP2A6 974/4885CA2 45/4885LMNA 1813/4885 |
| US-20040010004-A1 | Benzimidazole derivatives | CMA1, CBR3, CBR1 | CYP2A6 939/4885CA2 48/4885LMNA 1790/4885 |
| US-20050267148-A1 | Benzimidazole derivative | CMA1, SERPINB1, TPSAB1 | CYP2A6 726/4885CA2 125/4885LMNA 3900/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.